Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
CAPTOPRIL REDUCED PLASMINOGEN-ACTIVATOR INHIBITOR ACTIVITY IN PATIENTS WITH ACUTE MYOCARDIAL-INFARCTION
Autore:
OSHIMA S; TAKAZOE K; MORIYAMA Y; OGAWA H; HONDA Y; HIRASHIMA O; ARAI H; SAKAMOTO T; SUMIDA K; SUEFUJI H; KAIKITA K; YASUE H;
Indirizzi:
KUMAMOTO UNIV,SCH MED,DIV CARDIOL,1-1-1 HONJO KUMAMOTO 860 JAPAN KUMAMOTO UNIV,SCH MED,DIV CARDIOL KUMAMOTO 860 JAPAN FUKUOKA TOKUSYUKAI HOSP,DIV CARDIOL FUKUOKA JAPAN
Titolo Testata:
Japanese Circulation Journal
fascicolo: 4, volume: 61, anno: 1997,
pagine: 308 - 314
SICI:
0047-1828(1997)61:4<308:CRPIAI>2.0.ZU;2-K
Fonte:
ISI
Lingua:
ENG
Soggetto:
CORONARY-ARTERY DISEASE; T-PA ACTIVITY; VENTRICULAR DILATATION; ANGINA-PECTORIS; RISK; PLASMA; DEPRESSION; THERAPY; CHARACTERIZES; DYSFUNCTION;
Keywords:
CAPTOPRIL; PLASMINOGEN ACTIVATOR INHIBITOR; MYOCARDIAL INFARCTION;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
35
Recensione:
Indirizzi per estratti:
Citazione:
S. Oshima et al., "CAPTOPRIL REDUCED PLASMINOGEN-ACTIVATOR INHIBITOR ACTIVITY IN PATIENTS WITH ACUTE MYOCARDIAL-INFARCTION", Japanese Circulation Journal, 61(4), 1997, pp. 308-314

Abstract

Recent clinical trials have demonstrated that the administration of angiotensin-converting enzyme (ACE) inhibitors to patients with myocardial infarction reduces the incidence of recurrent myocardial infarction. It has also been reported that an elevated level of plasminogen activator inhibitor (PAI) appears to constitute a marker of the risk of recurrent coronary thrombosis. To determine whether the ACE inhibitor captopril reduces plasma PAI inhibitor activity, we measured changes inplasma PAI activity (IU/ml), tissue plasminogen activator (t-PA) antigen (ng/ml), and serum ACE activity (IU/L) in 14 survivors of myocardial infarction receiving captopril therapy (37.5 mg daily) and comparedthem with the values in 15 placebo-treated patients chosen at random. Blood sampling was performed at 07.00 h. In the captopril-treated group, serum ACE activity decreased significantly, from 14.0+/-0.8 to 11.5+/-1.2 IU/L 24 h after captopril therapy (p<0.01), and those of PAI activity and t-PA antigen also decreased significantly - from 11.9+/-2.8 to 5.5+/-2.2 IU/ml (p<0.02) and from 9.9+/-1.0 to 7.5+/-0.9 ng/ml (p<0.05), respectively 48 h after captopril therapy. However, the levelsof ACE activity, PAI activity, and t-PA antigen remained unchanged during the study period in the placebo group. Thus, our data indicate that the administration of captopril to patients with acute myocardial infarction may result in a reduced frequency of recurrent coronary thrombosis by increasing fibrinolytic capacity.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 27/11/20 alle ore 13:28:33